FDA Approves Eraxis to Treat Candidemia
Pfizer Inc's Eraxis (anidulafungin) has been approved by the FDA to treat candidemia, the most deadly of the common hospital-acquired bloodstream infections, with a mortality rate of approximately 40%, the company said in a news release.
NEW YORKPfizer Inc's Eraxis (anidulafungin) has been approved by the FDA to treat candidemia, the most deadly of the common hospital-acquired bloodstream infections, with a mortality rate of approximately 40%, the company said in a news release. The agent, an antifungal medicine of the echinocandin class, was also approved to treat two additional Candida infectionsperitonitis and intra-abdominal abscessesas well as esophageal candidiasis.
"In the clinical trial setting, patients taking Eraxis for the treatment of candidemia had improved efficacy vs those taking fluconazole," said lead clinical investigator Annette Reboli, MD, of Cooper University Hospital, Camden, New Jersey. "In addition, Eraxis has been shown to have a safety profile comparable to fluconazole and to be compatible with many medicines commonly used by candidemia patients who have other serious health complications."
Oncology Peer Review On-The-Go: Cancer-Related Fatigue Outcome Measures in Integrative Oncology
September 20th 2022Authors Dori Beeler, PhD; Shelley Wang, MD, MPH; and Viraj A. Master, MD, PhD, spoke with CancerNetwork® about a review article on cancer-related fatigue published in the journal ONCOLOGY®.
